Patents Examined by B. Dell Chism
-
Patent number: 7074758Abstract: The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from Indian Murrel brain, and further, a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.Type: GrantFiled: June 8, 2005Date of Patent: July 11, 2006Assignee: Council of Scientific and Industrial ResearchInventors: Abhijit Chatterjee, Partha Ray, Subrata Dasgupta, Samir Hattacharya, Santosh Pasha
-
Patent number: 7070969Abstract: The invention provides novel single stage competitive inhibitors of plasmin from the Australian brown snake Pseudonaja textilis textilis. The invention also features polynucleotides and polynucleotide homologues encoding these inhibitors. Pharmaceutical compositions containing the plasmin inhibitors of the invention are also disclosed as well as methods useful for treatment of blood loss.Type: GrantFiled: May 7, 1999Date of Patent: July 4, 2006Assignees: The University of Queensland, National Institute of Biological Standards and ControlInventors: Pantaleone Paul Masci, Martin Francis Lavin, Patrick Joseph Gaffney
-
Patent number: 7067486Abstract: The invention relates to a cell growth and/or differentiation regulatory peptide comprising a sequence of about 9 to about 150 amino acids derived from acetylcholinesterase amino acid sequence, preferably from the C-terminal region of acetylcholinesterase. The invention also relates to pharmaceutical compositions comprising the peptides, particularly for use in promoting survival of stem cells, promoting differentiation of stem cells, promoting growth of stem cells and/or promoting the growth-enhancing effect of a growth factor on stem cells, alone, or in combination with other growth factors. Of particular interest is the use of the peptides in the treatment of thrombocytopenia, post-irradiation conditions, post-chemotherapy conditions, or conditions following massive blood loss and promotion of neural progenitors in use for cell therapies aimed at restoring neural functions in diseased individuals.Type: GrantFiled: November 30, 2001Date of Patent: June 27, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Hermona Soreq, Sofia Eldor, legal representative, Varda Deutch, Dan Grisaru, Amiram Eldor, deceased
-
Patent number: 7041462Abstract: Methods and compositions are provided for identifying novel conformers of proteins not known to exist as different conformers. By using chimeric genes replacing a native signal sequence with a different signal sequence resulting in the production of a conformer, one can compare the native protein with the product of the chimeric gene. Where the conformations are different, the different protein may be used for production of antibodies, elucidation of mechanisms associated with the native and different conformer protein, assays for the presence of the different conformer in physiological samples, identification of compounds specifically binding to the conformer, particularly drugs, etc. Where the formation of the conformer is associated with a diseased state, the conformer may be used in screens to identify compounds as drug candidates.Type: GrantFiled: August 3, 2004Date of Patent: May 9, 2006Assignee: Regents of the University of CaliforniaInventors: Vishwanath R. Lingappa, D. Thomas Rutkowski, Ramanujan S. Hegde
-
Patent number: 7030213Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 26, 2001Date of Patent: April 18, 2006Assignee: La Jolla Cancer Research InstituteInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 7026287Abstract: The subject invention is directed to the treatment of tissue fibrosis by administration of an effective amount of lectin. Fibrosis herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Examples of tissue fibrosis include, but are not limited to, pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.Type: GrantFiled: May 12, 2003Date of Patent: April 11, 2006Inventors: Jerome Owen Cantor, Bronislava Shteyngart
-
Patent number: 7022671Abstract: Novel surfactant protein C esters suitable for preparing pharmaceutical compositions for the treatment of infant respiratory distress syndrome and adult respiratory distress syndrome are described.Type: GrantFiled: June 2, 2000Date of Patent: April 4, 2006Assignee: Altana Pharma AGInventors: Wolf-Rüdiger Ulrich, Ernst Sturm
-
Patent number: 7015305Abstract: Disclosed are processes for preparing glycopeptide antibiotic derivatives having an amino-containing side chain. The multi-step process is conducted in a single reaction vessel without isolation of intermediate reaction products.Type: GrantFiled: August 23, 2002Date of Patent: March 21, 2006Assignee: Theravance, Inc.Inventors: Junning Lee, Jyanwei Liu
-
Patent number: 7015021Abstract: The present disclosure relates to a single step method for purifying PAI-1, PAI-1 fragments and PAI-1 mutants using a metal chelate resin. The disclosure further relates to the purified PAI-1 obtained by the disclosed method and uses for the purified PAI-1.Type: GrantFiled: February 20, 2003Date of Patent: March 21, 2006Assignee: Molecular Innovations, Inc.Inventor: Duane D. Day
-
Patent number: 7008925Abstract: A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH2X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.Type: GrantFiled: May 5, 1999Date of Patent: March 7, 2006Assignee: Action Pharma A/SInventors: Michael Szardenings, Ruta Muceniece, Ilze Mutule, Felikss Mutulis, Jarl Wikberg
-
Patent number: 7005419Abstract: The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.Type: GrantFiled: June 20, 2003Date of Patent: February 28, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Xin Wei Wang, Curtis C. Harris, Albert J. Fornace, Jr., Jill D. Coursen, Qimin Zhan
-
Patent number: 6979673Abstract: Compositions containing cyclophilin B, mutants of cyclophilin B or inhibitors of cyclophilin B and methods of using these compositions to modulate somatolactogenic function are provided.Type: GrantFiled: August 10, 2000Date of Patent: December 27, 2005Assignee: Trustees of the University of PennsylvaniaInventors: Charles V. Clevenger, Michael A. Rycyzyn
-
Patent number: 6979672Abstract: A pharmaceutical formulation for the oral administration of cyclosporin is described, which formulation is capable of providing substantially constant and foreseeable plasma levels of the active ingredient. The formulation has the following quali-quantitative composition by weight: (a) cyclosporin in the amount of from about 8 to about 12% of the total weight; (b) ethanol in the amount of from about 12 to about 18% of the total weight; (c) a polyoxyethylene/polyoxypropylene block copolymer in the amount of from about 8 to about 12% of the total weight; (d) water in the amount of from about 4 to about 6% of the total weight; (e) a solubilizer having an HLB from 13 to 15 in the amount of from about 28 to about 40% of the total weight; (f) an ester of a C1-C6 alkyl alcohol and a C14-C18 saturated fatty acid in the amount of from about 20 to about 30% of the total weight.Type: GrantFiled: December 20, 2002Date of Patent: December 27, 2005Assignee: Polichem, S.A.Inventors: Michela Legora, Federico Mailland
-
Patent number: 6977242Abstract: The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from Indian Murrel brain, and further, a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.Type: GrantFiled: January 28, 2003Date of Patent: December 20, 2005Assignee: Council of Scientific and Industrial ResearchInventors: Abhijit Chatterjee, Partha Ray, Subrata Dasgupta, Samir Hattacharya, Santosh Pasha
-
Patent number: 6972122Abstract: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.Type: GrantFiled: December 18, 2001Date of Patent: December 6, 2005Assignees: Duke University, Yeda Research and Development Co., Ltd.Inventors: Zishan Haroon, Mark W. Dewhirst, Charles S. Greenberg, Michal Neeman
-
Patent number: 6967192Abstract: Peptide P, having the amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-His-Ser-Ile-NH2-SEQ ID NO:1, is useful to treat ischemia.Type: GrantFiled: March 11, 2003Date of Patent: November 22, 2005Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Mark S. Kindy
-
Patent number: 6960561Abstract: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.Type: GrantFiled: March 22, 2002Date of Patent: November 1, 2005Assignee: Aventis Pharma Deutschland GmbHInventor: Peter Boderke
-
Patent number: 6956027Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.Type: GrantFiled: October 4, 2002Date of Patent: October 18, 2005Assignee: Amgen Inc.Inventor: Olaf B. Kinstler
-
Patent number: 6927206Abstract: A method for treating rosacea of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, including active drug and active cosmetic substances. In a related aspect, further embodiments of the present invention are directed to compositions comprising at least one peptide copper complex and certain active drug and active cosmetic substances that render the compositions particularly effective in treating rosacea.Type: GrantFiled: June 6, 2003Date of Patent: August 9, 2005Assignee: ProCyte CorporationInventor: Leonard M. Patt
-
Patent number: 6927205Abstract: A method for treating psoriasis of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, including active drug and active cosmetic substances. In a related aspect, further embodiments of the present invention are directed to compositions comprising at least one peptide copper complex and certain active drug and active cosmetic substances that render the compositions particularly effective in treating psoriasis.Type: GrantFiled: April 28, 2003Date of Patent: August 9, 2005Assignee: ProCyte CorporationInventor: Leonard M. Patt